|
US 11,897,936 B2 |
|
| Peptides, combination of peptides as targets and for use in immunotherapy |
| Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Anita Wiebe, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE) |
| Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Aug. 27, 2021, as Appl. No. 17/458,670. |
| Application 17/458,670 is a continuation of application No. 17/401,678, filed on Aug. 13, 2021. |
| Application 17/401,678 is a continuation of application No. 16/814,532, filed on Mar. 10, 2020, granted, now 11,117,951. |
| Application 16/814,532 is a continuation of application No. 16/563,740, filed on Sep. 6, 2019, granted, now 10,669,326, issued on Jun. 2, 2020. |
| Application 16/563,740 is a continuation of application No. 15/602,746, filed on May 23, 2017, granted, now 10,464,990, issued on Nov. 5, 2019. |
| Claims priority of provisional application 62/341,367, filed on May 25, 2016. |
| Claims priority of application No. 1609193 (GB), filed on May 25, 2016. |
| Prior Publication US 2021/0403531 A1, Dec. 30, 2021 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07K 14/74 (2006.01); C12N 9/12 (2006.01); C07K 14/47 (2006.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01); C12N 15/115 (2010.01); C12N 5/0783 (2010.01); G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 7/08 (2006.01) |